Description

Illumina’s 95+ NovaSeq X Placements — A Powerful Consumables Flywheel Is Taking Shape!

The report on Illumina’s second quarter 2026 financial results highlighted a solid operational and financial performance, with several areas exhibiting notable growth alongside some ongoing challenges. Total revenue for the quarter reached $1.16 billion, reflecting a 9.5% year-over-year increase and 6.5% organic growth when adjusting for currency and acquisitions. The Rest of World (excluding China) organic growth rate stood at 8.1%, exceeding prior guidance. Margins and earnings per share (EPS) also surpassed expectations, with non-GAAP EPS at $1.31, up 10% year-over-year. Growth was largely driven by strong demand in clinical sequencing consumables, which represent about 65% of sequencing consumable revenue and grew 15% ex-China, led primarily by the U.S. and Canada region where growth exceeded 20%. Sequencing instrument revenue accelerated 31% year-over-year, fueled largely by increased placements of the NovaSeq X platform, with over 95 units placed during the quarter.